The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer Research

• Publication date

  2006-06-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/0008-5472.CAN-05-4187PMID 16740718
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.

  2006cited by this paper
• A Phase II Study of Dasatinib in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML) Who Are Resistant or Intolerant to Imatinib: First Results of the CA180005 ‘START-A’ Study.

  2005cited by this paper
• A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 ‘START-B’ Study.

  2005cited by this paper
• A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis or Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: The ‘START-L’ CA180015 Study.

  2005cited by this paper
• In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

  2005cited by this paper
• Dasatinib (BMS-354825) in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: Update of a Phase I Study.

  2005cited by this paper
• Efficacy of Dasatinib in Patients with Chronic Phase Philadelphia Chromosome-Positive CML Resistant or Intolerant to Imatinib: First Results of the CA180013 ‘START-C’ Phase II Study.

  2005cited by this paper
• Regulation of protein kinases; controlling activity through activation segment conformation.

  2004cited by this paper
• Optimisation of protein expression and establishment of the Wave Bioreactor for Baculovirus/insect cell culture

  2004cited by this paper
• Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.

  2004cited by this paper
• Biology of gastrointestinal stromal tumors.

  2004cited by this paper
• Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase*

  2004influential reference
• Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

  2004cited by this paper
• Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

  2004cited by this paper
• Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

  2003cited by this paper
• BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

  2003cited by this paper
• Chronic myeloid leukemia.

  2003cited by this paper
• Structural basis for the autoinhibition of c-Abl tyrosine kinase.

  2003cited by this paper
• Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

  2003cited by this paper
• Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.

  2002cited by this paper
• Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities.

  2002cited by this paper
• The conformational plasticity of protein kinases.

  2002cited by this paper
• A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.

  2002cited by this paper
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

  2002cited by this paper
• Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

  2002cited by this paper
• The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.

  2002cited by this paper
• Kinase inhibitors and the case for CH…O hydrogen bonds in protein–ligand binding

  2002cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001influential reference
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

  2001cited by this paper
• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

  2000cited by this paper
• Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

  2000cited by this paper
• The Protein Data Bank

  2000cited by this paper
• Outcome of Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia

  2000cited by this paper
• Chronic myeloid leukemia.

  1999cited by this paper
• Crystallography & NMR system: A new software suite for macromolecular structure determination.

  1998cited by this paper
• Processing of X-ray diffraction data collected in oscillation mode.

  1997cited by this paper
• Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation

  1996cited by this paper
• Active and inactive protein kinases: structural basis for regulation.

  1996cited by this paper
• AMoRe: an automated package for molecular replacement

  1994cited by this paper
• The CCP4 suite: programs for protein crystallography.

  1994cited by this paper
• Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

  1990cited by this paper
• Protein Data Bank

  1984cited by this paper
• On the treatment of negative intensity observations

  1978cited by this paper
• Electronic Reprint Biological Crystallography the Protein Data Bank Biological Crystallography the Protein Data Bank

  year unknowncited by this paper

• Expanding landscape of kinase inhibitor research in 25 years (2001-2025) and advancements of next-generation kinase inhibitors.

  2026cites this paper
• Molecularly targeted therapy and immunotherapy in leukemias

  2026cites this paper
• Toward the future management of patients with CML and Ph + ALL: real-world safety insights from dasatinib pharmacovigilance

  2026cites this paper
• Protein Language Models and Structure-Based Machine Learning for Prediction of Allosteric Binding Sites in Protein Kinases: An Explainable AI Framework Grounded in Energy Landscape-Encoded Frustration

  2026cites this paper
• Chromobox2 inhibition: a novel activity of alisertib, an aurora A kinase inhibitor.

  2026cites this paper
• Fyn–Saracatinib Complex Structure Reveals an Active State-like Conformation

  2026cites this paper
• Novel piperazine–pyrimidine hybrids as potential anticancer agents against MCF-7 breast carcinoma: synthesis, antimicrobial activity, antioxidant evaluation, and computational insights

  2026cites this paper
• Computer-aided design of imatinib derivatives: Overcoming drug-resistance in chronic myeloid leukemia

  2025cites this paper
• A universal model for drug-receptor interactions

  2025cites this paper
• Covalent Recruitment of NEDD4 for Targeted Protein Degradation: Rational Design of Small Molecular Degraders.

  2025cites this paper
• Prospective Evaluation of Structure-Based Simulations Reveal Their Ability to Predict the Impact of Kinase Mutations on Inhibitor Binding.

  2025cites this paper
• Allosteric binding cooperativity in kinases signaling, signalopathies, and drug development.

  2025cites this paper
• The recent advance of PROTACs targeting BCR-ABL for the treatment of chronic myeloid leukemia.

  2025cites this paper
• Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

  2025cites this paper
• Estimation of Absolute Binding Free Energies for Drugs That Bind Multiple Proteins

  2025cites this paper
• Estimating Boltzmann Statistical Energy for Proteins from 3D Structure Using Pairwise Amino Acid Energy Matrix - GEM-X2120-N871

  2025influential citation
• ATTEC-mediated degradation of BCR-ABL in chronic myeloid leukemia cells.

  2025cites this paper
• BCR::ABL1 kinase domain mutations and their predictive value for treatment outcomes in patients with chronic myeloid leukemia treated with first-line imatinib in a low-income setting: Experience from Côte d’Ivoire

  2025cites this paper
• Acute Lymphoid Leukemia: Is Transplant Indicated for Philadelphia Chromosome Positive ALL?

  2025cites this paper
• Discovery of pyrazole derivatives as promising leads against NSCLC: An integrated computational and experimental approach

  2025cites this paper
• 2B4 co-stimulation and dasatinib modulation enhance anti-CD19 CAR-NK-92 cell cytotoxicity

  2025cites this paper
• Selective Identification of Allosteric Inhibitors and Co-Drug Combinations Targeting Kinases by Using a Nanopore Tweezer Approach.

  2025cites this paper
• The c-Src inhibitor eCF506 diminishes opioid tolerance creating bias against β-arrestin2 recruitment

  2025cites this paper
• Prospective evaluation of structure-based simulations reveal their ability to predict the impact of kinase mutations on inhibitor binding

  2025cites this paper
• Cellular Selectivity Analyses Reveal Distinguishing Profiles for Type II Kinase Inhibitors

  2025cites this paper
• Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib.

  2025cites this paper
• Dasatinib is superior to imatinib in adult Ph + ALL: a propensity score-matched analysis of pooled JALSG trial data

  2025cites this paper
• Identification of new dasatinib analogues targeting mutated BCR-ABL1: virtual screening, molecular docking, and dynamics simulations studies.

  2025cites this paper
• Phosphorylation-inducing chimera rewires oncogenic kinase to trigger apoptosis

  2025cites this paper
• Dual Inhibition of SRC Family Kinases and Sorafenib Enhances Anti-Tumor Activity in Hepatocellular Carcinoma Cells

  2025cites this paper
• Palladium-Catalyzed [3 + 2] Annulation of o-Bromobenzyl Cyanide with Norbornene Derivatives via C(sp3)-H Bond Activation to Yield 1-Cyanoindane.

  2025cites this paper
• Exploring Inhibition Mechanisms in Wildtype and T315I BCR‐ABL1: An In Silico Approach Integrating Virtual Screening, MD Simulations, and MM‐GBSA Analysis

  2024cites this paper
• Design Principles and Applications of Fluorescent Kinase Inhibitors for Simultaneous Cancer Bioimaging and Therapy

  2024influential citation
• Mitochondrial-related drug resistance lncRNAs as prognostic biomarkers in laryngeal squamous cell carcinoma

  2024cites this paper
• Autophosphorylation of the oncogenic protein TEL-ABL confers resistance to the allosteric ABL inhibitor asciminib

  2024cites this paper
• Latent allosteric control of protein interactions by ATP-competitive kinase inhibitors.

  2024cites this paper
• Ponatinib: A Review of the History of Medicinal Chemistry behind Its Development

  2024cites this paper
• A Self-Assembled Nano-Molecular Glue (Nano-mGlu) Enables GSH/H2O2-Triggered Targeted Protein Degradation in Cancer Therapy.

  2024cites this paper
• Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring

  2024cites this paper
• Insights into existing and futuristic treatment approach for chronic myeloid leukaemia

  2024cites this paper
• Overcoming Secondary Mutations of Type II Kinase Inhibitors.

  2024cites this paper
• FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I.

  2024cites this paper
• Development of an Orally Bioavailable LCK PROTAC Degrader as a Potential Therapeutic Approach to T-Cell Acute Lymphoblastic Leukemia.

  2024cites this paper
• Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML

  2024cites this paper
• Tyrosine Kinase Inhibitors in Cancers: treatment optimization - Part I.

  2024cites this paper
• A case report of primary cutaneous diffuse large B-cell lymphoma in chronic myeloid leukemia after treatment with dasatinib

  2024cites this paper
• Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia

  2024influential citation
• Exploring the Impact of Protein Chain Selection in Binding Energy Calculations with DFT

  2024cites this paper
• Beyond IC50—A computational dynamic model of drug resistance in enzyme inhibition treatment

  2024cites this paper
• Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities

  2024cites this paper
• A Method for Treating Significant Conformational Changes in Alchemical Free Energy Simulations of Protein-Ligand Binding.

  2024cites this paper
• Structure‐Guided Drug Design Targeting Abl Kinase: How Structure and Regulation Can Assist in Designing New Drugs

  2024cites this paper
• Recent advances of small-molecule c-Src inhibitors for potential therapeutic utilities.

  2023cites this paper
• Antibody drug conjugates beyond cytotoxic payloads.

  2023cites this paper
• Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921

  2023cites this paper
• The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia.

  2023cites this paper
• Phosphorylated protein chip combined with artificial intelligence tools for precise drug screening

  2023cites this paper
• Harmonizing the Craft of Crafting Clinically Endorsed Small-Molecule BCR-ABL Tyrosine Kinase Inhibitors for the Treatment of Hematological Malignancies.

  2023cites this paper
• Long-Term Efficacy of High-Dose Imatinib in Hispanic Patients Without Access to Second-Generation Tyrosine Kinase Inhibitors Treated in LATAM Centers.

  2023cites this paper
• Structural mechanism of a drug-binding process involving a large conformational change of the protein target

  2023cites this paper
• The importance of personalized medicine in chronic myeloid leukemia management: a narrative review

  2023cites this paper
• Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity

  2023cites this paper
• Exploration of imatinib and nilotinib-derived templates as the P2-Ligand for HIV-1 protease inhibitors: Design, synthesis, protein X-ray structural studies, and biological evaluation.

  2023cites this paper
• Quantitatively Accounting for Protein Reorganization in Computer-Aided Drug Design.

  2023cites this paper
• Scaffold Hopping and Structural Modification of NSC 663284: Discovery of Potent (Non)Halogenated Aminobenzoquinones

  2023cites this paper
• What’s New in the Classification, Diagnosis and Therapy of Myeloid Leukemias

  2023cites this paper
• An idea to explore: Engaging high school students in structure‐function studies of bacterial sortase enzymes and inhibitors ‐ A comprehensive computational experimental pipeline

  2023cites this paper
• Novel pyrazolo[3,4-d]pyrimidines as dual Src/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatment.

  2022cites this paper
• A general tight-binding based energy decomposition analysis scheme for intermolecular interactions in large molecules.

  2022cites this paper
• Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors

  2022cites this paper
• Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety

  2022cites this paper
• The Structure-property Relationships of Clinically Approved Protein Kinase Inhibitors.

  2022cites this paper
• Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia

  2022cites this paper
• Synthetic Reprogramming of Kinases Expands Cellular Activities of Proteins.

  2022cites this paper
• Dasatinib is a potent enhancer for CAR T cell generation by CD3-targeted lentiviral vectors

  2022cites this paper
• Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India.

  2022cites this paper
• Development of optimized pyrimido-thiazole scaffold derivatives as anticancer and multitargeting tyrosine kinase inhibitors using computational studies

  2022cites this paper
• Fyn deficiency inhibits oxidative stress by decreasing c-Cbl-mediated ubiquitination of Sirt1 to attenuate diabetic renal fibrosis.

  2022cites this paper
• Evaluation of residue variability in a conformation‐specific context and during evolutionary sequence reconstruction narrows drug resistance selection in Abl1 tyrosine kinase

  2022cites this paper
• Systems-level conservation of the proximal TCR signaling network of mice and humans

  2022cites this paper
• Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19

  2022cites this paper
• Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia

  2022cites this paper
• Identification of defactinib derivatives targeting focal adhesion kinase using ensemble docking, molecular dynamics simulations and binding free energy calculations

  2022cites this paper
• Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases

  2022influential citation
• Identification and characterization of TYK2 pseudokinase domain stabilizers that allosterically inhibit TYK2 signaling.

  2022cites this paper
• Molecular dynamics simulations of the conformational plasticity in the active pocket of salt-inducible kinase 2 (SIK2) multi-state binding with bosutinib

  2022cites this paper
• Evolutionary divergence in the conformational landscapes of tyrosine vs serine/threonine kinases

  2022cites this paper
• BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia

  2022cites this paper
• Developing therapeutic approaches for chronic myeloid leukemia: a review

  2022cites this paper
• Formulation Characterization and Pharmacokinetic Evaluation of Amorphous Solid Dispersions of Dasatinib

  2022cites this paper
• Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis

  2022cites this paper
• Evolutionary Divergence in the Conformational Landscapes of Tyrosine vs Serine/Threonine Kinases

  2022cites this paper
• The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.

  2022cites this paper
• Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring

  2022cites this paper
• Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia

  2022cites this paper
• Molecular Docking, Molecular Dynamics Simulations, and Free Energy Calculation Insights into the Binding Mechanism between VS-4718 and Focal Adhesion Kinase

  2022cites this paper
• Activation of Abl1 Kinase Explored Using Well-Tempered Metadynamics Simulations on an Essential Dynamics Sampled Path

  2021cites this paper
• Targeted Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia—Therapy and Toxicity Mechanisms

  2021cites this paper
• CML Therapy: A Focus on Second- and Third-Generation Tyrosine Kinase Inhibitors

  2021cites this paper
• Investigation on the interaction behavior of afatinib, dasatinib, and imatinib docked to the BCR-ABL protein

  2021cites this paper